Aevi Genomic Medicine (GNMX) Misses Q1 EPS by 2c; to Initiate Phase 2 Trial of AEVI-001

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/16/2026

1. AMAT
2. GLOB
3. SPY
4. RDDT
5. HTFL
6. SNDK
7. WDAY
8. ADYEN:NA
9. DVLT
10. ADYYF

Go back to Aevi Genomic Medicine (GNMX) Misses Q1 EPS by 2c; to Initiate Phase 2 Trial of AEVI-001

Aevi (GNMX) PT Lowered to $1.50 at Jefferies Following 1Q

May 12, 2017 8:03 AM EDT

Jefferies lowered its price target on Aevi (NASDAQ: GNMX) to $1.50 (from $2.50) while maintaining a Hold rating.

GNMX reported 1Q EPS of -0.29 vs. -$0.24 estimates and opex of $11M. GNMX expects R&D expense to decrease with the SAGA study... More